News

CeNeS was up after a Phase III trial showed its key drug M6G provided equivalent pain relief to morphine but induced less post-operative nausea and vomiting.

"The significantly reduced sedation seen with M6G provides additional support to our view that M6G is equivalent to morphine in controlling pain but has a superior side-effect profile," said chief executive Neil Clark.

Cancer product development firm YM BioSciences said it has received a 'No Objection Letter' from Health Canada to go ahead with its phase II trial for its nimotuzumab drug.

The drug treats children who are resistant to existing treatments of brain cancer. It has already been approved for sale in India, China and certain Latin American countries.

"We remain optimistic that results will support the conclusion from previous trials: that our EGFR antibody has the potential to improve clinical outcomes with a superior safety profile compared to the other drugs in its class," said chairman and CEO David Allan.

Toymaker Character said its trading subsidiary Character Options has been awarded the master toy licence for TV-show Primeval.

"We will be producing an extensive line of exciting products that will include a Dragonfly Rex and Agnurognathus which will be available from this October and will be TV advertised," said Jon Diver, Joint Managing Director of Character.

Personal Screening said it is continuing to lose customers that it was unable to satisfy earlier in the year.

"The company raised new capital on admission to AIM in February 2006 and again in April 2006, in order to deal with this problem but was subsequently unable to prevent a further erosion of business," it said in a trading update

Sales for the first five months of 2007 came to £29,829. It added that it hopes to continue to grow at an increased rate during the remainder of the year.